Delivery Order SPE2DB22D9112-SPE2DB24FE6ST
Award Date
3/27/24
Potential Completion Date
4/17/24
Potential Value
$10K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of XOLAIR 150 MG/ML SYRINGEML to the Defense Logistics Agency, a component of the U.S. Department of Defense. The award is a firm fixed-price delivery order against DMS Pharmaceutical Group's existing indefinite delivery contract, SPE2DB, with a ceiling value of $4,642.20 and a period of performance through April 3, 2024. This larger IDV contract, valued at up to $4,999,999, enables the DLA to...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract worth $3,094.80 to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of XOLAIR 150 MG/ML syringes and has a performance period through May 2, 2024. This award is placed against DMS Pharmaceutical Group's existing indefinite delivery contract SPE2DB with DLA, valued at up to $4,999,999 through 2025. Under this broader contract vehicle, DMS Pharmaceutical Group...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $7,737.00 for the supply of XOLAIR 150 MG/ML SYRINGEML to the Defense Logistics Agency (DLA), which is the primary logistics and supply agency for the U.S. Department of Defense. The contract has an ultimate completion date of March 4, 2025 and is a firm fixed-price delivery order, with no set-aside designation. DMS Pharmaceutical Group Inc. holds...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of XOLAIR 150 MG/ML SYRINGEML pharmaceutical products to the Defense Logistics Agency (DLA) Medical Supply Chain. The firm fixed-price delivery order, valued at $3,094.80, has an ultimate completion date of October 22, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The $15,474.00 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) on November 18, 2024, with a completion date of December 10, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XOLAIR 150 MG/ML syringes. The contract is a firm fixed-price delivery order with a ceiling value of $7,737.00 and a period of performance through April 5, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery vehicle (IDV) contract, #4600082013 under the SPE2DB program, with DLA valued at up to $4,999,999 through the end of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of XOLAIR 150 MG/ML syringes. The total ceiling value of the order is $77,370.00, with an ultimate completion date of September 23, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a...
The U.S. Defense Logistics Agency Troop Support Medical has awarded a delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML. The firm fixed-price contract has a potential value of $1,547.40 and a completion date of February 22, 2024. This award is made under DMS Pharmaceutical Group's existing Indefinite Delivery Vehicle (IDV) contract 4600082013 with the Defense Logistics Agency, valued up to $4,999,999...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $9,284.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XOLAIR 150 MG/ML SYRINGE/ML. This delivery order is part of a larger, single-award indefinite delivery vehicle (IDV) contract, valued up to $4,999,999, that DMS Pharmaceutical Group holds with DLA to provide a broad range of pharmaceutical products and medical supplies to military health facilities...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide the pharmaceutical product XOLAIR 150 MG/ML SYRINGE. The contract has a potential value of $14,700.32 and a completion date of March 1, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that supplies a wide range of branded and generic pharmaceuticals to U.S. government agencies,...